156 related articles for article (PubMed ID: 23735326)
1. Intracellular observation of nanocarriers modified with a mitochondrial targeting signal peptide.
Kawamura E; Yamada Y; Yasuzaki Y; Hyodo M; Harashima H
J Biosci Bioeng; 2013 Nov; 116(5):634-7. PubMed ID: 23735326
[TBL] [Abstract][Full Text] [Related]
2. Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier.
Yamada Y; Harashima H
Mitochondrion; 2013 Sep; 13(5):526-32. PubMed ID: 23000575
[TBL] [Abstract][Full Text] [Related]
3. Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter.
Yamada Y; Harashima H
Biomaterials; 2012 Feb; 33(5):1589-95. PubMed ID: 22105068
[TBL] [Abstract][Full Text] [Related]
4. A Dual-Ligand Liposomal System Composed of a Cell-Penetrating Peptide and a Mitochondrial RNA Aptamer Synergistically Facilitates Cellular Uptake and Mitochondrial Targeting.
Yamada Y; Furukawa R; Harashima H
J Pharm Sci; 2016 May; 105(5):1705-1713. PubMed ID: 27056631
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial targeting functional peptides as potential devices for the mitochondrial delivery of a DF-MITO-Porter.
Kawamura E; Yamada Y; Harashima H
Mitochondrion; 2013 Nov; 13(6):610-4. PubMed ID: 24012978
[TBL] [Abstract][Full Text] [Related]
6. Multifunctional envelope-type nano device for controlled intracellular trafficking and selective targeting in vivo.
Kajimoto K; Sato Y; Nakamura T; Yamada Y; Harashima H
J Control Release; 2014 Sep; 190():593-606. PubMed ID: 24794902
[TBL] [Abstract][Full Text] [Related]
7. Validation of a Strategy for Cancer Therapy: Delivering Aminoglycoside Drugs to Mitochondria in HeLa Cells.
Abe J; Yamada Y; Harashima H
J Pharm Sci; 2016 Feb; 105(2):734-740. PubMed ID: 26523487
[TBL] [Abstract][Full Text] [Related]
8. Mitochondria-Targeting Peptoids.
Nam HY; Hong JA; Choi J; Shin S; Cho SK; Seo J; Lee J
Bioconjug Chem; 2018 May; 29(5):1669-1676. PubMed ID: 29578690
[TBL] [Abstract][Full Text] [Related]
9. Bifunctional peptide hybrids targeting the matrix of mitochondria.
Klimpel A; Neundorf I
J Control Release; 2018 Dec; 291():147-156. PubMed ID: 30367921
[TBL] [Abstract][Full Text] [Related]
10. [Development of the MITO-porter, a nano device for mitochondrial drug delivery via membrane fusion].
Yamada Y
Yakugaku Zasshi; 2014; 134(11):1143-55. PubMed ID: 25366911
[TBL] [Abstract][Full Text] [Related]
11. Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery.
Yamada Y; Furukawa R; Yasuzaki Y; Harashima H
Mol Ther; 2011 Aug; 19(8):1449-56. PubMed ID: 21694702
[TBL] [Abstract][Full Text] [Related]
12. A mitochondrial delivery system using liposome-based nanocarriers that target myoblast cells.
Katayama T; Kinugawa S; Takada S; Furihata T; Fukushima A; Yokota T; Anzai T; Hibino M; Harashima H; Yamada Y
Mitochondrion; 2019 Nov; 49():66-72. PubMed ID: 31326598
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial delivery of bongkrekic acid using a MITO-Porter prevents the induction of apoptosis in human HeLa cells.
Yamada Y; Nakamura K; Furukawa R; Kawamura E; Moriwaki T; Matsumoto K; Okuda K; Shindo M; Harashima H
J Pharm Sci; 2013 Mar; 102(3):1008-15. PubMed ID: 23315986
[TBL] [Abstract][Full Text] [Related]
14. A multifunctional envelope-type nanodevice for use in nanomedicine: concept and applications.
Nakamura T; Akita H; Yamada Y; Hatakeyama H; Harashima H
Acc Chem Res; 2012 Jul; 45(7):1113-21. PubMed ID: 22324902
[TBL] [Abstract][Full Text] [Related]
15. From serendipity to mitochondria-targeted nanocarriers.
Weissig V
Pharm Res; 2011 Nov; 28(11):2657-68. PubMed ID: 21833792
[TBL] [Abstract][Full Text] [Related]
16. Tailoring nanocarriers for intracellular protein delivery.
Gu Z; Biswas A; Zhao M; Tang Y
Chem Soc Rev; 2011 Jul; 40(7):3638-55. PubMed ID: 21566806
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial delivery of Coenzyme Q10 via systemic administration using a MITO-Porter prevents ischemia/reperfusion injury in the mouse liver.
Yamada Y; Nakamura K; Abe J; Hyodo M; Haga S; Ozaki M; Harashima H
J Control Release; 2015 Sep; 213():86-95. PubMed ID: 26160304
[TBL] [Abstract][Full Text] [Related]
18. Innovative Technologies in Nanomedicines: From Passive Targeting to Active Targeting/From Controlled Pharmacokinetics to Controlled Intracellular Pharmacokinetics.
Sato Y; Sakurai Y; Kajimoto K; Nakamura T; Yamada Y; Akita H; Harashima H
Macromol Biosci; 2017 Jan; 17(1):. PubMed ID: 27797146
[TBL] [Abstract][Full Text] [Related]
19. Targeting the mitochondrial genome via a dual function MITO-Porter: evaluation of mtDNA levels and mitochondrial function.
Yamada Y; Harashima H
Methods Mol Biol; 2015; 1265():123-33. PubMed ID: 25634272
[TBL] [Abstract][Full Text] [Related]
20. ICAM-1 targeting, intracellular trafficking, and functional activity of polymer nanocarriers coated with a fibrinogen-derived peptide for lysosomal enzyme replacement.
Garnacho C; Muro S
J Drug Target; 2017; 25(9-10):786-795. PubMed ID: 28665212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
